Update on insulin therapy for type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1405-1413

  Donner, Thomas ^a   Muñoz, Miguel ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; EXENDIN 4; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LINJETA; METFORMIN; METFORMIN PLUS PIOGLITAZONE; ORAL ANTIDIABETIC AGENT; PIG INSULIN; PIOGLITAZONE; PLACEBO; RECOMBINANT HUMAN INSULIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; U 500; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CONTINUOUS INFUSION; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; GLYCOSYLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN TREATMENT; MACROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84860773338     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2202     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention 2011 National diabetes factsheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Last accessed July 12, 2011
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 2008 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
3. Shichiri M, Kishikawa H, Ohkubo Y, Wake N 2000 Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23(Suppl 2):B21-B29
4. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD 2009 Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
5. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT 2008 Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
6. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F 2008 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572
7. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J 2008 Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 155:26-32, 32.e1-e6
8. Leahy JL, Hirsch IB, Peterson KA, Schneider D 2010 Targeting/3-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 95:4206-4216
9. 1995 U. K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
11. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G 2008 A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51:408-416
12. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK 2009 Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736-1747
13. Raskin P, Gylvin T, Weng W, Chaykin L 2009 Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 25:542-548
14. Bazzano LA, Lee LJ, Sh IL, Reynolds K, Jackson JA, Fonseca V 2008 Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 25:924-932
15. Mannucci E, Monami M, Marchionni N 2009 Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a metaanalysis. Diabetes Obes Metab 11:53-59
16. Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A 2009 Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral agents). Diabetes Obes Metab 11:27-32
17. Davidson MB, Navar MD, Echeverry D, Duran P 2010 U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 33:281-283
18. Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM 2009 Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 94:729-740
19. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K 2011 Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 92:1-10
20. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S 2010 The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340:b5444
21. Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B 2009 Hypoglycemia unawareness in older compared with middleaged patients with type 2 diabetes. Diabetes Care 32:1513-1517
22. de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, Macmahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M 2009 Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 52:2328-2336
23. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V 2003 Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 26:1485-1489
24. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME 2010 The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909
25. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T 2008 Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073-1084
26. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Jarvinen H, Heine RJ 2009 One-year treatment with exenatide improves/3-cell function, compared with insulin glargine, in metformintreated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32:762-768
27. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C 2010 Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33:1509-1515
28. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J 2011 Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154:103-112
29. Hollander P, Cooper J, Bregnhøj J, Pedersen CB 2008 A 52-week, multinational, open-label, parallel-group, noninferiority, treat-totarget trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 30:1976-1987
30. Buse JB, Wolffenbuttel BH, Herman WH, Hippler S, Martin SA, Jiang HH, Shenouda SK, Fahrbach JL 2011 The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care 34:249-255
31. Charbonnel B, De Fronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V, Scheen A 2010 Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 95:2163-2171
32. Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF 2011 Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 13:268-275
33. Peyrot M, Rubin RR, Kruger DF, Travis LB 2010 Correlates of insulin injection omission. Diabetes Care 33:240-245
34. Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU 2011 Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism? Diabet Med 28:276-286
35. Zinma NB, Fulcher G, Rao PV, Thoma SN, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstoc KJ, Pinge TM, Mathieu C 2011 Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet 377:924-931
36. S. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, Pfützner A, Heinemann L 2008 A novel insulin formulation with a more rapid onset of action. Diabetologia 51:1602-1606
37. Forst T, Pfützner A, Flacke F, Krasner A, Hohberg C, Tarakci E, Pichotta P, Forst S, Steiner S 2010 Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes Care 33:116-120
38. Kramer I, Sauer T 2010 The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis 10:163-171
39. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
40. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S 2011 Individualizing glycemic targets in type 2 diabetes mellitus: implicationsof recent clinical trials. Ann Intern Med 154:554-559